Latest: FDA Approves New Biosimilar for Oncology Treatment

Do SDOH Drive Survival Outcomes With Brexu-Cel in ALL?

28 August, 2025

0 Mins

Race, ethnicity, and social factors can influence survival outcomes in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) receiving brexucabtagene autoleucel (brexu-cel).

Tags:

Author

American Journal Managed Care

10 Common Medications That May Be Disrupting Your Body’s Nutrient Balance

NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression

📢

300x250 Banner

Do SDOH Drive Survival Outcomes With Brexu-Cel in ALL?

Tags:

American Journal Managed Care

10 Common Medications That May Be Disrupting Your Body’s Nutrient Balance

NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition